Key facts
- This page summarizes Samuel Agresta's Form 4 filing for Foghorn Therapeutics Inc. (FHTX).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 13 Sep 2023, 16:02.
Samuel Agresta - 11 Sep 2023 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- FHTX
- Reported as of
- 11 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Sep 2023, 16:02:28 UTC
- Prior SEC filing
- 18 Aug 2023
- Next SEC filing
- 08 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- /s /Allan Reine, M.D., Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Samuel Agresta filed Form 4 for Foghorn Therapeutics Inc. (FHTX) on 13 Sep 2023.
Change
- Previous filing in this sequence was filed on 18 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FHTX
holding
Derivative
Stock Options (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 100,000
- Date
- 11 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $16.63
- Footnotes
- F1
FHTX
holding
Derivative
Stock Options (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 125,000
- Date
- 11 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 125,000
- Exercise price
- $14.87
- Footnotes
- F2
FHTX
holding
Derivative
Stock Options (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 91,891
- Date
- 11 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 91,891
- Exercise price
- $8.77
- Footnotes
- F3
FHTX
holding
Derivative
Stock Options (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 60,000
- Date
- 11 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,000
- Exercise price
- $8.38
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Samuel Agresta is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
The option vested as to 25% of the underlying shares of common stock on January 28, 2022, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter.
Footnote F2
The option vested as to 25% of the underlying shares of common stock on January 26, 2023, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter.
Footnote F3
The option vested as to 25% of the underlying shares of common stock on August 17, 2021, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter.
Footnote F4
The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
SEC remarks
Exit Form 4 filed solely to report the Reporting Person is no longer an officer of the Issuer within the meaning of Rule 16a-1 of the Securities Exchange Act of 1934, as amended.